UA90108C2 - Способи одержання сполук боронового естеру та кислоти - Google Patents

Способи одержання сполук боронового естеру та кислоти

Info

Publication number
UA90108C2
UA90108C2 UAA200611339A UAA200611339A UA90108C2 UA 90108 C2 UA90108 C2 UA 90108C2 UA A200611339 A UAA200611339 A UA A200611339A UA A200611339 A UAA200611339 A UA A200611339A UA 90108 C2 UA90108 C2 UA 90108C2
Authority
UA
Ukraine
Prior art keywords
acid compounds
synthesis
boronic ester
boronic
acid
Prior art date
Application number
UAA200611339A
Other languages
English (en)
Russian (ru)
Inventor
І. Фрейзер Пікерсджилл
Джон Бішоп
Крістоф Келльнер
Жан-Марк Гомес
Ахім Гайзер
Роберт Хетт
Вінс Еммоскейто
Стефен Манк
Янг Ло
Фан-Тін Чуй
Вітхалананд Р. Кулкарні
Original Assignee
Мілленніум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90108(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мілленніум Фармасьютікалз, Інк. filed Critical Мілленніум Фармасьютікалз, Інк.
Publication of UA90108C2 publication Critical patent/UA90108C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cпособи одержання сполуки боронового естеру формули (І), аміноборонового естеру (VІІ) і бортезомібу інгібітора протеасоми (ХІV), в якій R1 являє собою необов'язково заміщену С1-8аліфатичну, С6-10арильну або (С6-10арил)(С1-6аліфатичну) групу; R2 являє собою водень або хлор; R3 являє собою хлор; і кожен з R4 і R5, незалежно, являє собою необов'язково заміщену С1-12аліфатичну, С6-14ароматичну або 5-14-членну гетероароматичну групу, або R4 і R5, взяті разом з проміжними атомами кисню і бору, утворюють необов'язково заміщений 5-10-членний цикл, що містить 0-2 додаткових циклічних гетероатоми, які вибирають з N, О або S; де вказаний спосіб включає: (a) забезпечення бор "ат" комплексу формули (II): в якій Y являє собою нуклеофужну групу; М+ являє собою катіон; і кожен з R1-R5 є таким, як визначено вище; і (b) контактування бор "ат" комплексу формули (II) з кислотою Льюїса в умовах, за яких одержують сполуку боронового естеру формули (І), де вказану стадію контактування проводять в реакційній суміші, яка містить: (і) координуючий естерний розчинник, який має низьку міру змішуваності з водою; або (іі) естерний розчинник, який має низьку міру змішуваності з водою, і координуючий співрозчинник; де розчинність води у кожному естерному розчиннику, що має низьку міру змішуваності з водою, становить менш, ніж 5 мас. %; (c) промивання реакційної суміші водним розчином; і (d) концентрування промитої реакційної суміші шляхом видалення розчинників з одержанням залишку, який містить сполуку боронового естеру формули (І) EMBED ISISServer , (І) EMBED ISISServer , (VІІ) EMBED ISISServer , (ХІV) EMBED ISISServer (II).
UAA200611339A 2004-03-30 2005-03-24 Способи одержання сполук боронового естеру та кислоти UA90108C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30
PCT/US2005/009774 WO2005097809A2 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds

Publications (1)

Publication Number Publication Date
UA90108C2 true UA90108C2 (uk) 2010-04-12

Family

ID=34968044

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611339A UA90108C2 (uk) 2004-03-30 2005-03-24 Способи одержання сполук боронового естеру та кислоти

Country Status (41)

Country Link
US (14) US7714159B2 (uk)
EP (5) EP1756121B1 (uk)
JP (4) JP4558039B2 (uk)
KR (1) KR100939598B1 (uk)
CN (5) CN1960996B (uk)
AR (3) AR049374A1 (uk)
AT (1) ATE521612T1 (uk)
AU (1) AU2005230930B2 (uk)
BR (1) BRPI0509587A (uk)
CA (4) CA2738706C (uk)
CL (2) CL2010000350A1 (uk)
CR (1) CR8653A (uk)
CY (3) CY1112053T1 (uk)
DK (4) DK3385267T3 (uk)
DO (1) DOP2011000293A (uk)
EA (1) EA012927B1 (uk)
EC (1) ECSP066960A (uk)
ES (3) ES2899606T3 (uk)
FI (1) FI4008721T3 (uk)
HK (4) HK1100004A1 (uk)
HR (4) HRP20212002T1 (uk)
HU (1) HUE056859T2 (uk)
IL (3) IL178250A (uk)
LT (2) LT3385267T (uk)
ME (1) ME01975B (uk)
MX (1) MX367324B (uk)
MY (1) MY145427A (uk)
NL (3) NL1028639C2 (uk)
NO (4) NO338905B1 (uk)
NZ (3) NZ586824A (uk)
PE (3) PE20142402A1 (uk)
PL (4) PL2377869T3 (uk)
PT (4) PT1756121E (uk)
RS (4) RS51983B (uk)
SG (5) SG10201800972PA (uk)
SI (4) SI1756121T1 (uk)
TW (1) TWI386212B (uk)
UA (1) UA90108C2 (uk)
UY (3) UY28830A1 (uk)
WO (1) WO2005097809A2 (uk)
ZA (1) ZA200608689B (uk)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2738706C (en) 2004-03-30 2014-10-14 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
EP2527347A1 (en) * 2007-08-06 2012-11-28 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
AU2008298694A1 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2730580A1 (en) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2013204881A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
CN102803271B (zh) * 2009-06-19 2016-03-23 力奇制药公司 氢化卤代烯烃而不脱卤的方法
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations
EP2552216B1 (en) 2010-03-31 2018-01-24 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
WO2014041324A1 (en) * 2012-09-11 2014-03-20 Cipla Limited Process for preparing of bortezamib
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
WO2014076713A2 (en) 2012-11-16 2014-05-22 Shilpa Medicare Limited Crystalline bortezomib process
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2909519A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
EP3145526A1 (en) 2014-05-20 2017-03-29 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
CN109988186A (zh) 2014-06-11 2019-07-09 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
KR20190127681A (ko) 2017-02-17 2019-11-13 프레세니어스 카비 온콜로지 리미티드 붕소산 에스테르의 개선된 제조방법
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019020099A1 (zh) 2017-07-28 2019-01-31 成都地奥九泓制药厂 一种硼酸酯化合物、其合成方法及其用途
MX2020002187A (es) 2017-09-02 2020-09-22 Sun Pharmaceutical Ind Ltd Proceso para la preparacion de citrato de ixazomib.
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525309A (en) 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
WO2003033506A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
CA2738706C (en) 2004-03-30 2014-10-14 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
CN102803271B (zh) * 2009-06-19 2016-03-23 力奇制药公司 氢化卤代烯烃而不脱卤的方法

Also Published As

Publication number Publication date
US9862745B2 (en) 2018-01-09
NO338905B1 (no) 2016-10-31
SI4008721T1 (sl) 2024-05-31
DK1756121T3 (da) 2012-01-09
ATE521612T1 (de) 2011-09-15
HUE056859T2 (hu) 2022-03-28
HK1164320A1 (en) 2012-10-19
SI2377869T1 (sl) 2014-05-30
US20050240047A1 (en) 2005-10-27
HRP20212002T1 (hr) 2022-04-01
UY28830A1 (es) 2005-09-30
SG10201600029PA (en) 2016-02-26
WO2005097809A3 (en) 2006-02-16
EP4008721A1 (en) 2022-06-08
RS53259B (en) 2014-08-29
JP2007530687A (ja) 2007-11-01
EP3385267A1 (en) 2018-10-10
US20150038706A1 (en) 2015-02-05
PT4008721T (pt) 2024-03-21
PT1756121E (pt) 2011-11-30
AR097309A2 (es) 2016-03-02
IL219853A (en) 2015-05-31
DOP2011000293A (es) 2011-12-15
JP2010241816A (ja) 2010-10-28
JP2013100378A (ja) 2013-05-23
NL1028639A1 (nl) 2005-10-20
HRP20140339T1 (hr) 2014-05-09
AU2005230930B2 (en) 2011-09-29
US20210171574A1 (en) 2021-06-10
EP3385267B1 (en) 2021-09-29
US8283467B2 (en) 2012-10-09
SG10201800972PA (en) 2018-03-28
ME01975B (me) 2015-05-20
NO343966B1 (no) 2019-07-29
JP5414625B2 (ja) 2014-02-12
ZA200608689B (en) 2007-09-26
EP2377868A1 (en) 2011-10-19
US7714159B2 (en) 2010-05-11
NO20171939A1 (no) 2006-12-22
JP6193960B2 (ja) 2017-09-06
JP2016056180A (ja) 2016-04-21
MY145427A (en) 2012-02-15
TWI386212B (zh) 2013-02-21
NZ586824A (en) 2012-03-30
CL2010000350A1 (es) 2011-01-28
US10000529B2 (en) 2018-06-19
RS65253B1 (sr) 2024-03-29
LT3385267T (lt) 2021-11-10
SG182999A1 (en) 2012-08-30
CN103396427B (zh) 2018-04-13
JP4558039B2 (ja) 2010-10-06
LT4008721T (lt) 2024-03-25
CA2560886A1 (en) 2005-10-20
SI1756121T1 (sl) 2012-03-30
UY35578A (es) 2016-01-08
EP1756121B1 (en) 2011-08-24
NO344610B1 (no) 2020-02-10
US20200157143A1 (en) 2020-05-21
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
SG151322A1 (en) 2009-04-30
EP4008721B1 (en) 2024-01-03
US20100174072A1 (en) 2010-07-08
CN1960996B (zh) 2016-04-20
CA2859119A1 (en) 2005-10-20
NO20064893L (no) 2006-12-22
NL1033189A1 (nl) 2007-10-22
NO20191065A1 (no) 2006-12-22
PT2377869E (pt) 2014-04-15
HRP20110846T1 (hr) 2011-12-31
PT3385267T (pt) 2021-11-23
CA2560886C (en) 2014-08-12
PL1756121T3 (pl) 2012-02-29
CY1115336T1 (el) 2017-01-04
FI4008721T3 (fi) 2024-03-19
US20180044377A1 (en) 2018-02-15
NL1033189C2 (nl) 2008-08-14
ES2899606T3 (es) 2022-03-14
US20190330270A1 (en) 2019-10-31
EP1756121A2 (en) 2007-02-28
TW200616646A (en) 2006-06-01
NZ550522A (en) 2010-08-27
EA200601795A1 (ru) 2007-04-27
EP2377869A1 (en) 2011-10-19
EA012927B1 (ru) 2010-02-26
CN108329337A (zh) 2018-07-27
BRPI0509587A (pt) 2007-09-25
IL178250A0 (en) 2006-12-31
ES2457593T3 (es) 2014-04-28
US20210395301A1 (en) 2021-12-23
US20220204558A1 (en) 2022-06-30
IL219856A (en) 2015-05-31
CY1112053T1 (el) 2015-11-04
NL1033190A1 (nl) 2007-04-23
IL219856A0 (en) 2012-06-28
PL4008721T3 (pl) 2024-05-13
DK2377869T3 (da) 2014-04-14
PE20110075A1 (es) 2011-02-17
ECSP066960A (es) 2006-12-20
PE20060162A1 (es) 2006-04-07
PL3385267T3 (pl) 2022-02-14
NL1033190C2 (nl) 2007-11-27
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
US20160362449A1 (en) 2016-12-15
WO2005097809A2 (en) 2005-10-20
AU2005230930A1 (en) 2005-10-20
CN1960996A (zh) 2007-05-09
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
SG182998A1 (en) 2012-08-30
US20200369722A1 (en) 2020-11-26
SI3385267T1 (sl) 2022-04-29
CN111925385B (zh) 2023-11-21
HK1246300A1 (zh) 2018-09-07
NO20161350A1 (no) 2006-12-22
RS62738B1 (sr) 2022-01-31
CN108329337B (zh) 2021-06-25
JP5894952B2 (ja) 2016-03-30
CL2014002252A1 (es) 2014-12-05
CY1124753T1 (el) 2022-07-22
AR049374A1 (es) 2006-07-26
CN111925385A (zh) 2020-11-13
DK4008721T3 (da) 2024-03-25
CN107474062A (zh) 2017-12-15
PL2377869T3 (pl) 2014-07-31
ES2371652T3 (es) 2012-01-05
PE20142402A1 (es) 2015-02-04
NZ598172A (en) 2013-08-30
US20190112334A1 (en) 2019-04-18
KR20070007873A (ko) 2007-01-16
IL219853A0 (en) 2012-06-28
MX367324B (es) 2019-08-15
HK1257298A1 (zh) 2019-10-18
US20180265546A1 (en) 2018-09-20
UY34969A (es) 2015-02-27
CA2738706A1 (en) 2005-10-20
EP2377869B1 (en) 2014-01-29
AR097310A2 (es) 2016-03-02
KR100939598B1 (ko) 2010-02-01
HRP20240307T3 (hr) 2024-05-10
HK1100004A1 (en) 2007-08-31
DK3385267T3 (da) 2021-11-01
CA2738706C (en) 2014-10-14

Similar Documents

Publication Publication Date Title
SG151322A1 (en) Synthesis of boronic ester and acid compounds
PL1758852T3 (pl) Podstawione związki cyklopentenu
MX2007004426A (es) Procesos para preparar telmisartan.
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
UA102817C2 (uk) Спосіб синтезу агомелатину
MX2007003118A (es) Procedimiento de intermediarios para preparar inhibidores de cisteina proteasa.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
MX2010010660A (es) Nuevos complejos de rutenio como catalizadores para reacciones de metatesis.
UA102220C2 (uk) Спосіб синтезу агомелатину
IL180354A0 (en) Process for the preparation of atomoxetine hydrochloride
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
UA94837C2 (uk) Спосіб синтезу (7-метокси-1-нафтил)ацетонітрилу і застосування у синтезі агомелатину
PL1670778T3 (pl) Przegrupowane pentanole, sposób ich wytwarzania i ich zastosowanie jako środków hamujących zapalenia
MX2012003488A (es) Proceso para la elaboracion de n-acil-bifenil-alanina.
TW200612959A (en) Method for preparing hydroxamic acids
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
TW200806304A (en) Maitake mushroom extract and composition containing the same for enhance production of sebum
SG158860A1 (en) Processes for the preparation of aminoethoxybenzyl alcohols
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.
MX2009007598A (es) Hexahidrato de enrofloxacino.
TW200728267A (en) Processes and intermediates for the preparation of prostaglandins
SG155231A1 (en) Process for synthesis of dialkoxyorganoboranes
PL1856125T3 (pl) Synteza prekursora inhibitora proteazy
MX2007012472A (es) (+)-y-(-)-8-alquil-3-(trifluoralquilsulfoniloxi)-8-azabicicl (3.2.1)cot-2-eno.